Clinical Trials Logo

SF3B1 Gene Mutation clinical trials

View clinical trials related to SF3B1 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04447651 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

PRISMM
Start date: September 17, 2020
Phase:
Study type: Observational [Patient Registry]

This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.